Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
Roche Pharma AG
Sanofi-Synthelabo
All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 PO BID was administered on days 1-14 of each cycle.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
To be included in this study, you must meet the following criteria:
Histologically confirmed carcinoma of unknown primary site
Progressive disease after treatment with one previous chemotherapy regimen.
Treatment with one previous immunotherapy or biotherapy regimen.
No previous treatment with oxaliplatin, capecitabine, or 5-FU.
Previous treatment with other platinum agents
Patients must have measurable or evaluable disease
ECOG Performance Status more than 2
Adequate bone marrow, liver and kidney function
Understand the nature of this study and give written informed consent.
You may not be if
You cannot participate in this study if any of the following apply to you:
Age \< 18 years
History of treatment of any invasive malignancy within the last 5 years
Coexistent medical illnesses
Clinically significant cardiac disease
Preexisting peripheral neuropathy \> grade 1
Lack of physical integrity of the upper gastrointestinal tract
Pre-existing uncontrolled coagulopathy
Women who are pregnant or lactating
Clareo Health | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
